MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » Thoratec shareholder seeks class action over recall, blood clot study

Thoratec shareholder seeks class action over recall, blood clot study

January 28, 2014 By Brad Perriello Leave a Comment

Share
Thoratec shareholder seeks class action over blood clot recall

An owner of Thoratec (NSDQ:THOR) stock is suing the heart pump maker on behalf of himself and other shareholders, accusing the medical device company of failing to warn investors about a blood clot problem with its HeartMate II implant implicated in a Class I recall.

The FDA in 2012 classed a Thoratec field correction as a Class I recall, saying an improperly connected component may result in deformation or tearing of the device’s outflow conduit, creating the risk of serious injury or death. Last year a study, published in the New England Journal of Medicine, documented a sharp increase in the rate of blood clots with the HeartMate II left ventricular assist device. Each episode pushed THOR share prices down.

That’s prompted Bradley Cooper to sue on behalf of anyone who bought the stock between April 29, 2010, and Nov. 27, 2013. Cooper alleges that Thoratec misled investors about the risk of thrombosis, or blood clots, in the HeartMate II device. He bought a total of 460 Thoratec shares between July 2010 and July 2013, according to court documents; a block of 200 shares July 27, 2010 for $44.29 apiece; another 30 shares at $42.80 the next day; and a final 230-share block for $31.21 apiece on July 15, 2013.

The stock was trading at $34.34 per share as of about 11:35 a.m. today, down 0.1%.

"As a result of defendants’ wrongful acts and omissions, and the precipitous decline in the market value of the company’s securities, plaintiff and other class members have suffered significant damages," according to the lawsuit.

The Pleasanton, Calif.-based device maker issued a correction notice in February 2012, warning physicians that a small portion of the HeartMate II devices’ sealed outflow graft bend reliefs, designed to prevent a connector between the pump and the aorta from kinking, were not properly connected.

The issue was reported in less than 1% of 3,200 devices and most cases were discovered in X-ray images or during surgical procedures. It may have been a contributor to at least 1 patient’s need for replacement surgery. Detached bend reliefs can cause low or fluctuating pump flow, hemolysis, varying speed and/or power or worsening symptoms of heart failure, and "may cause serious adverse health consequences, including death," according to the FDA.

"The firm states that the device labeling has been revised to provide instructions on how to verify the bend relief is fully engaged with the sealed outflow graft at the time of implant and new caution statement regarding the bend relief connection are included," according to the FDA warning. "Clinicians have been instructed to follow the revised instructions for use that clarify the recommended procedure for securing the bend relief to the outflow graft."

Then, last November, the NEJM article reported a sharp increase in rates of blood clots in patients implanted with the HeartMate II, using data from 3 centers that implanted more than 830 of the devices from January 2004 through May 2013. Data from 3 centers that implanted 895 HeartMate II LVADs in 837 patients from January 2004 through May 2013 showed a total of 72 confirmed cases of pump thrombosis in 66 patients and another 36 cases of suspected pump thrombosis. Of note were a drastic increase after March 2011, according to the study, when rates jumped from 2.2% at 3 months to 8.4% by January 2013. The study also revealed a sharp decrease in the amount of time from implantation with the HeartMate II device until blood clots developed.

Earlier this month Thoratec CEO Gary Burbach said the NEJM study, involving by then year-old data from only 3 centers, obscured the fact that adverse events associated with the HeartMate II are down.

"The broader context is that survival has actually improved since the clinical trial, quite significantly here in the commercial experience," Burbach said at the J.P. Morgan healthcare conference in San Francisco. "We’ve also seen significant improvements in other areas – adverse events, stroke, bleeding and infection, in particular."

Filed Under: Legal News, News Well, Wall Street Beat Tagged With: Thoratec Corp.

In case you missed it

  • Here’s how a new Abbott device is making a difference among neonatal infants
  • Conformis: Yale study shows customized knee implants save money
  • Intuitive Surgical wins FDA clearance for robotic-assisted lung biopsy system
  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
  • Phillips-Medisize is expanding in Wisconsin
  • NuVasive wins FDA, CE Mark for Precice internal bone transport system
  • Cash-strapped Aradigm declares bankruptcy
  • ReWalk Robotics files for exoskeleton suit clearance
  • Hancock Jaffe launches first-in-human VenoValve study
  • Medtronic shares rise on FY2019 Q3 earnings beat
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system
  • India CDSCO adds new medical devices to regulated list
  • Judge sends ‘brain fingerprinting company’ and would-be distributor to arbitration
  • FDA gives massive Medtronic recall Class I designation
  • Affluent Medical touts results of endovascular aneurysm repair study

RSS From Medical Design & Outsourcing

  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
    Medtronic officials continue to hone their arguments for how the company’s capnography and oximetry systems could reduce potentially deadly opioid-induced respiratory compromise. The medical device giant on Feb. 17 announced preliminary results of its Prodigy study, in which the company’s Microstream and Nellcor monitoring technology provided continuous capnography and oximetry for 1,496 patients across 16 sites in the U.S.,… […]
  • Phillips-Medisize is expanding in Wisconsin
    Phillips-Medisize, a Molex company, has broken ground on a new manufacturing facility in Hudson, Wis., on the eastern end of the Minneapolis-St. Paul metro area. The 34-acre location at the St. Croix Meadows development will support at least 230,000 square feet of manufacturing space for FDA-regulated medical device products, Phillips-Medisize announced yesterday. After construction is complete… […]
  • ReWalk Robotics files for exoskeleton suit clearance
      ReWalk Robotics (NSDQ:RWLK) said it has applied to FDA for 510(k) clearance of its ReStore exoskeleton suit for gait training during stroke rehabilitation. The Yokneam, Israel-based company designed its exo-suit to provide coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. It recently won insurer reimbursement from Cigna and completed a clinical… […]
  • FDA proposes faster post-inspection feedback
    FDA has issued draft guidance providing for more timely nonbinding feedback following medtech facility inspections to advise whether the companies’ proposed corrective actions appear adequate to the agency. The draft guidance proposes a process by which companies can request nonbinding feedback on certain kinds of observations issued on a Form 483. It outlines a standardized method… […]
  • India CDSCO adds new medical devices to regulated list
    By Stewart Eisenhart, Emergo Group India’s Central Drugs Standard Control Organization (CDSCO) continues expanding oversight to more types of medical devices, now planning to require registration for eight additional device types starting April 1, 2020. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s… […]
  • Empowering Medical Innovation
    From faster medical device development to life-saving surgical planning models, see how full-color, multi-material 3D printing opens up broad possibilities for medical innovation. In this new E-book you’ll learn how the Stratasys J750 can: Produce superior medical models for surgical planning and training Foster better medical devices through faster ideation and prototyping Enable advanced training… […]
  • Affluent Medical touts results of endovascular aneurysm repair study
    Medtech startup Affluent Medical(Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent… […]
  • This cotton-based biofuel cell could power implanted medical devices
    Researchers at the Georgia Institute of Technology and Korea University have developed a glucose-powered biofuel cell that uses electrodes from cotton that could potentially power implantable medical devices. The fuel cell has twice as much power as traditional biofuel cells and could also be paired with batteries or super capacitors to create a hybrid power… […]
  • IEEE publishes safety standards draft for medtech interoperability
    The Institute of Electrical and Electronics Engineers (IEEE) Standards Association said it has published a draft set of standards intended to provide safe and secure medical device interoperability. IEEE 11073-20701-2018, also known as IEEE Approved Draft Standard for Service-Oriented Medical Device Exchange Architecture & Protocol Binding, completes the International Organization for Standardization (ISO)/IEEE 11073 family of standards… […]
  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively.… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS